The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial.
 
Tetsuya Eto
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Merck Serono; Takeda; Yakult Pharmaceutical
 
Dai Manaka
No Relationships to Disclose
 
Junichi Hasegawa
No Relationships to Disclose
 
Akinori Takagane
No Relationships to Disclose
 
Masato Nakamura
Honoraria - Chugai Pharma; Merck serono; Takeda
 
Takeshi Kato
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma; Yakult Honsha
Expert Testimony - Lilly
Travel, Accommodations, Expenses - Eisai
 
Yoshinori Munemoto
No Relationships to Disclose
 
Fumitaka Nakamura
No Relationships to Disclose
 
Hiroyuki Bandou
No Relationships to Disclose
 
Hiroki Taniguchi
No Relationships to Disclose
 
Makio Gamoh
No Relationships to Disclose
 
Manabu Shiozawa
No Relationships to Disclose
 
Takeharu Yamanaka
No Relationships to Disclose
 
Tsunekazu Mizushima
No Relationships to Disclose
 
Junichi Sakamoto
No Relationships to Disclose
 
Shigetoyo Saji
No Relationships to Disclose
 
Masaki Mori
No Relationships to Disclose
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Takayuki Yoshino
No Relationships to Disclose